DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Testicular Germ Cell Tumor — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTesticular Germ Cell Tumor maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for testicular germ cell tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serine/threonine kinase 10 (STK10) — STK10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet trifluoromethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6EIM · 1.43 Å · ligand ~{N}-[5-[4-[[2-fluoranyl-5-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-1~{H}-benzimidazol-2-yl]furan-2-carboxamide (B6E). Experimental structure, not a prediction.
What the evidence adds up to
Testicular germ cell tumours arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminomas have features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminomas show varied differentiation. The tumours show high sensitivity to chemotherapies, but 20–30% of patients show resistance to standard chemotherapy. Genomic studies are examining gene expression as possible markers for disease relapse and chemotherapy resistance.
Cure rates for testicular cancer have improved dramatically over the past 30 years, with 5-year survival approaching 95%. More than 80% of men who present with metastatic disease are now cured, compared with about 15% in the early 1970s. This improvement is attributed to the integration of effective treatments and staging modalities, particularly the introduction of cisplatin. However, advanced and platinum-refractory disease states continue to be challenging entities in terms of optimising therapy and outcome.
Optimal treatment strategies for early-stage nonseminomatous tumours continue to evolve, and patient compliance with posttreatment surveillance schedules remains problematic. Long-term survivorship issues are also being evaluated. Staging currently represents the cornerstone on which treatment is based, and because most patients will be cured, attention has shifted toward reducing morbidity of treatment while maintaining high cure rates. This implies that staging must be accurate before any change to the treatment regimen can be instituted.
Significant challenges remain for treatment of certain categories of testicular germ cell tumours. What is still missing is a reliable way to identify the 20–30% of patients who will become resistant to standard chemotherapy before they relapse, and effective therapies for those with platinum-refractory disease. Better patient stratification tools and trials designed to test reduced-toxicity regimens without compromising the high cure rate are also needed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Urology · 2018 · 37 citations · open access
Current knowledge of risk factors for testicular germ cell tumors
AbstractThe development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned.
The International Journal of Developmental Biology · 2013 · 10 citations · open access
Testicular germ cell tumors and related research from a historical point of view
AbstractIn this brief overview of the history of testicular germ cell tumors, we touch upon the key events and personalities that have contributed to our current understanding of germ cell tumors in general, and those of the testis in particular. The intricacies of human germ cell tumor pathology and histogenesis have been elucidated in part by contributions in the field of experimental pathology and developmental biology. Correlation between clinical oncologic findings, pathology and experimental studies of germ cell tumors and related topics ushered the era of cellular and genetic engineering that have revolutionized contemporary cell and molecular biology.
AbstractPURPOSE OF REVIEW: To discuss several important developments in testicular germ cell tumors in the past year. RECENT FINDINGS: Genomic studies are examining gene expression as possible markers for disease relapse and chemotherapy resistance. Optimal treatment strategies for early-stage nonseminomatous tumors continue to evolve and patient compliance with posttreatment surveillance schedules remains problematic. Advanced and platinum-refractory disease states continue to be challenging entities in terms of optimizing therapy and outcome. SUMMARY: Significant challenges remain for treatment of certain categories of testicular germ cell tumors. Treatment and surveillance paradigms continue to be defined and refined as research in these areas continues.
AbstractPURPOSE OF REVIEW: This overview discusses several important developments in testicular germ cell tumors in the last year. RECENT FINDINGS: Genomic studies are examining gene expression as possible markers for disease relapse and chemotherapy resistance. Optimal treatment strategies for early-stage nonseminomatous tumors continue to evolve, and advanced disease states continue to be challenging entities in terms of optimizing therapy and outcome. Long-term survivorship issues are also being evaluated in this patient population. SUMMARY: Significant challenges remain for treatment of certain categories of testicular germ cell tumors. Treatment and surveillance paradigms continue to be defined and refined as research in these areas continues.
Important factors in the diagnosis and primary staging of testicular tumours
AbstractPURPOSE OF REVIEW: In the present review we outline the use of different staging methods and highlight future possibilities in the management of testicular germ cell cancer. RECENT FINDINGS: The 5-year survival for testicular cancer has improved dramatically over the past 30 years, with cure rates approaching 95%. This success is attributed to the appropriate integration of effective treatments and staging modalities. Staging currently represents the cornerstone on which treatment is based. Because most patients will be cured, attention has shifted toward reducing morbidity of treatment while maintaining high cure rates. This implies that staging must be accurate before any change to the treatment regimen can be instituted. SUMMARY: Effective management of testicular germ cell cancer continues to pose a major challenge. Early and accurate diagnosis is very important because it will influence the choice of treatment and thus may impact on prognosis.
International Journal of Urological Nursing · 2008 · 1 citations
Testicular cancer before and after cisplatin: a 30‐year view
AbstractAbstract Exciting changes have been made in the management of testicular germ cell cancers over the past 30 years. Today, more than 80% of men who present with metastatic disease are cured compared with about 15% in the early 1970s. This means that there are a large number of survivors and many of them have willingly provided information that can be used in shaping the management of other malignancies. The paper aims to summarize the current management of testicular germ cell cancers comparing the situation in the pre‐platinum era with that today and to consider current and future developments in the management of this disease.
Current Cancer Therapy Reviews · 2018 · 0 citations
Systemic Therapies for Metastatic Testicular Germ Cell Tumors: Past, Present and Future
AbstractTesticular germ cell tumors (TGCTs) are unique to that of most other solid tumors because they are highly curable in the metastatic setting. While the use of cisplatin-based chemotherapy continues to drive cure in this patient population, important improvements in the delivery of therapy, creation of risk-adjusted treatment paradigms, and salvage-therapy options have further enhanced survival as well. The future holds promise for a more multidisciplinary approach to care, through advancements in biochemical markers and a better understanding of how surgical and radiotherapy approaches can integrate into our existing management strategies.
Humana Press eBooks · 2004 · 0 citations · open access
Laparoscopic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumors of the Testis
AbstractThe management of testicular cancer has changed dramatically since the early 1980s because of highly effective chemotherapy and improvements in surgical technique. The long-term survival and cure rate even for advanced stages of all germ cell tumors is excellent. As such, there is now increased emphasis on developing treatment regimens that attain a high cure rate while minimizing patient morbidity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
